Bronchial hyperresponsiveness in asthmatic adults--a long-term correlation study.

Area of Science:

• Pulmonology
• Allergy and Immunology
• Clinical Medicine

Background:

• Bronchial hyperresponsiveness (BHR) is a key risk factor and complex feature of asthma.
• The relationship between BHR, asthma severity, and long-term therapeutic interventions remains incompletely understood.
• No prior studies have investigated the correlation between BHR in mild persistent asthmatic adults and five-year treatment outcomes.

Purpose of the Study:

• To evaluate the role of BHR in the clinical assessment of asthma.
• To determine the correlation between BHR and asthma therapy over a five-year period.

Main Methods:

• Seventy adult patients with mild allergic (seasonal/perennial) and non-allergic asthma were recruited.
• Patients received various inhaled medications and immunotherapy based on asthma type.
• Bronchial hyperresponsiveness (BHR) was assessed using methacholine challenge tests (PD20 FEV1) at baseline, after two years, and annually for five years in a subset of patients.

Main Results:

• Despite clinical symptom improvement with therapy, BHR levels showed no statistically significant changes in any patient group at two or five years.
• No significant correlation was observed between clinical symptom presentation and BHR (PD20 FEV1) values.
• Individual patient data revealed varied responses, but overall trends did not support a direct impact of therapy on BHR.

Conclusions:

• Long-term asthma therapy, including inhaled corticosteroids and immunotherapy, does not significantly modify BHR in mild persistent asthmatic adults.
• BHR is unlikely to be a reliable biomarker for asthma disease activity or a predictive tool for guiding therapeutic decisions.
• Further research is warranted to explore the multifactorial nature of BHR and its complex interplay with asthma pathophysiology.